{"id":"metformin-sibutramine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (metformin)"},{"rate":"5-10","effect":"Tachycardia (sibutramine)"},{"rate":"5-15","effect":"Hypertension (sibutramine)"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL3989830","moleculeType":"Small molecule","molecularWeight":"334.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases gluconeogenesis and enhances peripheral glucose uptake, improving glycemic control. Sibutramine is a sympathomimetic amine that acts as a serotonin-norepinephrine reuptake inhibitor, promoting satiety and reducing caloric intake. The combination targets both metabolic dysfunction and obesity-related complications in diabetic patients.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:38.366Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus with obesity"}]},"trialDetails":[{"nctId":"NCT05821543","phase":"PHASE4","title":"Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-07-03","conditions":"Obesity","enrollment":240},{"nctId":"NCT00941382","phase":"PHASE3","title":"Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients","status":"UNKNOWN","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2008-11","conditions":"Obesity","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reduxin® Forte"],"phase":"marketed","status":"active","brandName":"metformin+sibutramine","genericName":"metformin+sibutramine","companyName":"Promomed, LLC","companyId":"promomed-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes. Used for Type 2 diabetes mellitus with obesity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}